Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUMIT: Selumetinib + Dacarbazine in Metastatic Uveal Melanoma
NCT01974752Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 11
01
Overview
A Phase 3 trial of selumetinib in Uveal melanoma (UM), sponsored by AstraZeneca. Started Apr 2014; status: completed.
02
Drugs
selumetinib
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT01974752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01974752.